Poster lunch (ID 46) Poster display session

44P - Prognostic value of Ki-67 in patients with triple-negative breast cancer receiving neo-adjuvant or adjuvant chemotherapy: A systematic review and meta-analysis (ID 196)

Presentation Number
44P
Lecture Time
12:15 - 12:15
Speakers
  • Qinghua Zhou (Chengdu, China)
Session Name
Poster lunch (ID 46)
Location
Exhibition area, MARITIM Hotel Berlin, Berlin, Germany
Date
03.05.2019
Time
12:15 - 13:00

Abstract

Background

Ki-67 is a widely used marker of tumor proliferation, but the prognostic value of Ki-67 in triple-negative breast cancer (TNBC) is still controversial. The aim of present meta-analysis was conducted to evaluate the association between Ki-67 expression and survival in TNBC patients receiving neo-adjuvant or adjuvant chemotherapy.

Methods

Relevant literatures were identified from PubMed, Embase, Web of Science, China National Knowledge Infrastructure, and Cochrane Library, up to March 14, 2018. Hazard ratio (HR) with 95% confidence intervals (CI) were calculated as effect values, and heterogeneity, sensitivity analysis and publication bias analyses were also performed.

Results

35 studies enrolling 7716 patients were eligible for inclusion. Data on overall survival (OS) and disease-free survival (DFS) were available from 25 and 29 studies, respectively. The pooled results showed that high Ki-67 expression was significantly associated with poor DFS (HR: 1.73, 95% CI: 1.45–2.07, p < 0.001) and OS (HR: 1.65, 95% CI: 1.27–2.14, p < 0.001) compared with low Ki-67 expression in TNBC. Similar results were observed on subgroup analysis by Ki-67 or ER/PR cut-off value, treatment strategies, or districts.

Conclusions

High Ki-67 was a poor prognostic factor for TNBC who received neo-adjuvant or adjuvant chemotherapy.

Legal entity responsible for the study

Wen Li.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

Collapse